secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2025-08-20T23:59:59+00:00
Accession:  0001104659-25-080470
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance settles YUPELRI patent litigation with Cipla; generic launch date April 23, 2039
--------------------------------------------------------------------------------

- Settlement resolves Hatch-Waxman patent litigation on YUPELRI (revefenacin) inhalation solution.
- Cipla granted royalty-free license to market generic version in U.S. on or after April 23, 2039.
- Settlement subject to review by U.S. DOJ and FTC as required by law.
- Patent litigation remains pending against Mankind Pharma Ltd. and affiliates (another ANDA filer).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465925080470/0001104659-25-080470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465925080470/tm2523736d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-080470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer